TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells

Lipids in Health and Disease

Ning Xu¹  Peter Nilsson-Ehle¹  Maria Berggren-Söderlund¹  Yuanping Shi³  Jiang Wei³  Zongchun Wang²  Guanghua Luo³  Xiaoying Zhang²  Dongmei Di²  Chunhua Zhu² 

[1] Division of Clinical Chemistry and Pharmacology, Department of Laboratory Medicine, Lunds University, S-221 85 Lund, Sweden;Department of Cardiothoracic Surgery, Third Affiliated Hospital of Suzhou University, Changzhou 213003, P.R. China;Comprehensive Laboratory, Third Affiliated Hospital of Suzhou University, Changzhou 213003, P.R. China

关键词: Apolipoprotein M;    Caco-2 cell line;    Farnesoid X Receptor;    Liver X Receptor;   

Others  :  1212455
DOI  :  10.1186/1476-511X-10-199

 received in 2011-09-22, accepted in 2011-11-04,  发布年份 2011

【 摘 要 】

Background

Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a liver X receptor (LXR) agonist, TO901317.

Materials and methods

Caco-2 cells were cultured in the presence of either TO901317, farnesoid X receptor (FXR) antagonist guggulsterone or TO901317 together with guggulsterone at different concentrations for 24 hrs. The mRNA levels of ATP-binding cassette transporter A1 (ABCA1), apoA1, apoM, liver receptor homologue-1 (LRH-1) and short heterodimer partner 1 (SHP1) were determined by real-time RT-PCR.

Results

When Caco-2 cell cultured with TO901317 alone, the mRNA levels of ABCA1, apoA1, apoM, LRH-1 and SHP1 were significantly increased with dose-dependent manners (p < 0.05), whereas when the cells cultured with guggulsterone alone, the mRNA levels of apoM, SHP1 and LRH-1 (p < 0.05) were strongly inhibited. Moreover, guggulsterone could abolish the TO901317 enhanced mRNA levels of apoA1 apoM, SHP1 and LRH-1.

Conclusion

The present study demonstrated that LXR agonist TO901317 induced apoM expression in Caco-2 cells might be mediated via the LXR/FXR pathway.

【 授权许可】

   
2011 Zhu et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Briffa TG, Sanfilippo FM, Hobbs MS, Ridout SC, Katzenellenbogen JM, Thompson PL, Thompson SC: Under-ascertainment of Aboriginality in records of cardiovascular disease in hospital morbidity and mortality data in Western Australia: a record linkage study. BMC Med Res Methodol 2010, 10:111-116. BioMed Central Full Text
• [2]Vardavas CI, Linardakis MK, Hatzis CM, Saris WH, Kafatos AG: Cardiovascular disease risk factors and dietary habits of farmers from Crete 45 years after the first description of the Mediterranean diet. Eur J Cardiovasc Prev Rehabil 2010, 17(4):440-446.
• [3]Andrikoula M, McDowell IF: The contribution of ApoB and ApoA1 measurements to cardiovascular risk assessment. Diabetes Obes Metab 2008, 10(4):271-278.
• [4]Panayiotou A, Griffin M, Georgiou N, Bond D, Tyllis T, Tziakouri-Shiakalli C, Fessas C, Nicolaides A: ApoB/ApoA1 ratio and subclinical atherosclerosis. Int Angiol 2008, 27(1):74-80.
• [5]Arsenault BJ, Boekholdt SM, Kastelein JJ: Lipid parameters for measuring risk of cardiovascular disease. Nat Rev Cardiol 2011, 8(4):197-206.
• [6]Xu N, Dahlback B: A novel human apolipoprotein (apoM). J Biol Chem 1999, 274(44):31286-31290.
• [7]Christoffersen C, Nielsen LB, Axler O, Andersson A, Johnsen AH, Dahlback B: Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47(8):1833-1843.
• [8]Christoffersen C, Obinata H, Kumaraswamy SB, Galvani S, Ahnstrom J, Sevvana M, Egerer-Sieber C, Muller YA, Hla T, Nielsen LB, et al.: Endothelium-protective sphingosine-1-phosphate provided by HDL-associated apolipoprotein M. Proc Natl Acad Sci USA 2011.
• [9]Wolfrum C, Poy MN, Stoffel M: Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis. Nat Med 2005, 11(4):418-422.
• [10]Christoffersen C, Jauhiainen M, Moser M, Porse B, Ehnholm C, Boesl M, Dahlback B, Nielsen LB: Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice. J Biol Chem 2008, 283(4):1839-1847.
• [11]Venteclef N, Haroniti A, Tousaint JJ, Talianidis I, Delerive P: Regulation of anti-atherogenic apolipoprotein M gene expression by the orphan nuclear receptor LRH-1. J Biol Chem 2008, 283(7):3694-3701.
• [12]Mosialou I, Zannis VI, Kardassis D: Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem 2010, 285(40):30719-30730.
• [13]Zhang Y, Chen CJ, Yang QL, Cheng LQ, Wang H, Huang LZ: [Effect of interfering hepatocyte nuclear factor-1 alfa in HepG2 on the expressions of apoM, apoA-I and the correlative key enzyme of cholesterol metabolism.]. Zhonghua Gan Zang Bing Za Zhi 2011, 19(2):121-126.
• [14]Li X, Yeh V, Molteni V: Liver X receptor modulators: a review of recently patented compounds (2007 - 2009). Expert Opin Ther Pat 2010, 20(4):535-562.
• [15]Zhang X, Zhu Z, Luo G, Zheng L, Nilsson-Ehle P, Xu N: Liver X receptor agonist downregulates hepatic apoM expression in vivo and in vitro. Biochem Biophys Res Commun 2008, 371(1):114-117.
• [16]Calayir E, Becker TM, Kratzer A, Ebner B, Panzenbock U, Stefujl J, Kostner GM: LXR-agonists regulate ApoM expression differentially in liver and intestine. Curr Pharm Biotechnol 2008, 9(6):516-521.
• [17]Huang XS, Zhao SP, Hu M, Luo YP: Apolipoprotein M likely extends its anti-atherogenesis via anti-inflammation. Med Hypotheses 2007, 69(1):136-140.
• [18]Feingold KR, Shigenaga JK, Chui LG, Moser A, Khovidhunkit W, Grunfeld C: Infection and inflammation decrease apolipoprotein M expression. Atherosclerosis 2008, 199(1):19-26.
• [19]Luo G, Zhang X, Mu Q, Chen L, Zheng L, Wei J, Berggren-Soderlund M, Nilsson-Ehle P, Xu N: Expression and localization of apolipoprotein M in human colorectal tissues. Lipids Health Dis 2010, 9:102. BioMed Central Full Text
• [20]Jiang J, Wu C, Luo G, Zheng L, Chen L, Zhang X, Xu N: Expression of apolipoprotein M in human hepatocellular carcinoma tissues. Acta Histochem 2011, 113(1):53-57.
• [21]Houck KA, Borchert KM, Hepler CD, Thomas JS, Bramlett KS, Michael LF, Burris TP: T0901317 is a dual LXR/FXR agonist. Mol Genet Metab 2004, 83(1-2):184-187.
• [22]Li G, Thomas AM, Hart SN, Zhong X, Wu D, Guo GL: Farnesoid X receptor activation mediates head-to-tail chromatin looping in the Nr0b2 gene encoding small heterodimer partner. Mol Endocrinol 2010, 24(7):1404-1412.
• [23]Huuskonen J, Vishnu M, Chau P, Fielding PE, Fielding CJ: Liver X receptor inhibits the synthesis and secretion of apolipoprotein A1 by human liver-derived cells. Biochemistry 2006, 45(50):15068-15074.